The CEO of Peptech told the Australian Biotechnology Summit the nation's top biotech companies have to adopt strategies for merger and acquisitions to build growth, expand the product line and cut investor risk. John Chiplin says the country's top 10 biotech companies should be focusing on M&A activity.

Related Summaries